Research It is a rare disease that causes malformations in blood vessels. The study has discovered the implication of a protein in the development of the pathology.
Researchers identify a possible therapy against Rendu-Osler disease Read More »
The Ramón Areces Foundation has awarded Grants for Research in Life Sciences and Matter corresponding to its 20th edition. In intercellular dialogue and interactome area, Dr. Isabel Fabregat, head of the research group “TGF-beta and cancer” at IDIBELL, in collaboration with Drs. Aránzazu Sánchez and Blanca Herrera from the Complutense University of Madrid, have received one of the grants.
60% of Covid-19 inpatients develop neurological symptoms and 12% of post-Covid patients have neurological sequelae.
60% of Covid-19 patients develop neurological symptoms Read More »
This year within the framework of the Hospitalet Spring Festival, we enjoyed again in the Science Park.
Saturday was the day to enjoy and experiment in the Hospitalet science park Read More »
IDIBELL and the Virolai school, together in a new educational initiative of the Escolab program of the Barcelona City Council
We launch VacunAcció: a project to immunize against fake news Read More »
Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital had launched a clinical study, along with the pharmaceutical company Takeda, to evaluate the efficacy and safety of Icatibant as a treatment against COVID-19.
The work of the Epidemiology of Bacterial Infections research group of IDIBELL and HUB indicates that the bacteria could achieve the resistance through the acquisition of mobile DNA fragments.
Last Tuesday, April 20th, within the Areté Training Program, the IDIBELL AES-2020 Kick Off Meeting was held, aimed at all researchers who have obtained a health research project within the “2020 AES Call” funded by the ISCIII.
IDIBELL celebrates the Kickoff Meeting on Health Research Projects awarded by ISCIII Read More »
A study led by IDIBELL and the Infanta Eleonor University Hospital in Madrid shows that 10% of patients with severe COVID-19 present neutralizing antibodies against the cytokine interferon type 1.
We found that there were epigenetic variations, the chemical switches that regulate DNA activity, in the individuals positive for the virus who developed a severe COVID-19.
Discovery of Epigenetic Factors. Predicting the Severity of COVID-19 Read More »
